Procalcitonin Reveals Early Dehiscence in Pancreatic Surgery: the PREDIPS Study

University of Roma La Sapienza

Status

Unknown

Conditions

Pancreatic Cancer

Treatments

Other: pts operated for pancreatic cancer

Study type

Observational

Funder types

Other

Identifiers

NCT02756468

PREDIPS

Details and patient eligibility

About

Background. Pancreatic cancer surgery is associated with very high risk of postoperative morbidity and mortality. Anastomotic leak (AL) is one of the worst complications associated with relevant short and long-term sequelae. Procalcitonin (PCT) is a biomarker used to monitor bacterial infections and guide antibiotic therapy and has been shown to have better predictive value of AL after colorectal surgery than C-reactive protein (CRP) and white blood cell count (WBC).

Purpose. The investigators designed a monocentric pilot study to test if PCT might be a sensitive and reliable marker of AL after pancreatic surgery

Enrollment

100 estimated patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

patients undergoing all different kinds of pancreatic surgery
in elective setting
for cancer
with a pancreatic anastomosis performed.

Exclusion criteria

age < 18 years
pregnant women
patients undergoing pancreatic surgery for benign disease, other kinds of pancreatic surgery without an anastomosis being performed